NasdaqGS - Delayed Quote USD

Akoya Biosciences, Inc. (AKYA)

Compare
2.2100 +0.0100 (+0.45%)
At close: June 14 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Brian McKelligon President, CEO & Director 854.99k -- 1969
Mr. John Frederick Ek CFO, Principal Financial Officer & Principal Accounting Officer 496.76k -- 1976
Dr. Frederic G. Pla Ph.D. Chief Operating Officer 581.23k -- 1959
Priyam Shah Senior Director of Business Development & Investor Relations Strategy -- -- --
Ms. Jennifer Kamocsay General Counsel -- -- 1971
Dr. Niro Ramachandran Ph.D. Chief Business Officer 298.18k -- 1975
Dr. Pascal Bamford Ph.D. Senior Vice President, Research & Development and Laboratory Operations -- -- --
Mr. Rob C. Hart CFA, J.D. Secretary -- -- --

Akoya Biosciences, Inc.

100 Campus Drive
6th Floor
Marlborough, MA 01752
United States
855 896 8401 https://www.akoyabio.com
Sector: 
Healthcare
Full Time Employees: 
330

Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Akoya Biosciences, Inc.’s ISS Governance QualityScore as of June 1, 2024 is 8. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 5, 2024 at 10:59 AM UTC - August 9, 2024 at 12:00 PM UTC

Akoya Biosciences, Inc. Earnings Date

Recent Events

June 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 13, 2024 at 9:00 PM UTC

Q1 2024 Earnings Call

May 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 23, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 5, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 4, 2024 at 10:00 PM UTC

Q4 2023 Earnings Call

March 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 10, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers